Revision Total Hip Replacement Arthroplasty and Hematologic Variables

Seoul National University Bundang Hospital62 enrolled

Overview

Revision total hip replacement arthroplasty is a surgery having intra- and postoperative substantial blood loss. The investigators will investigate the relationship between the various hematologic variables and postoperative bleeding volume.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Avascular Necrosis of Hip Degenerative Hip Joint Disease

Interventions

RTHRA groupOTHER

hematologic variables measurement in patients undergoing revision total hip replacement

Eligibility

Sex: ALLMin age: 20 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * revision total hip replacement Exclusion Criteria: * hematologic disease * anticoagulant medication * American Society of Anesthesiologists physical status 4 and 5

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

Change of FIBTEM

FIBTEM: one of the measurements of the rotational thromboelastometry

Time frame: 5 minutes before initiation of anesthesia and 5 minutes after finishing operation

Secondary Outcomes

volume of infused fluid during operation

Infused total crystalloid and colloid volume during the operation will be recorded

Time frame: Period from starting to finishing the operation (During operation, an expected average of 3 hours)

intraoperative urine output

Time frame: Period from starting to finishing the operation (During operation, an expected average of 3 hours)

transfusion units

Red blood cell

Time frame: Period from starting to finishing the operation (During operation, an expected average of 3 hours) and postoperative first day

postoperative bleeding volume

Time frame: postoperative 72 hours

Hemoglobin

Time frame: preoperative day 1

Hemoglobin

Time frame: postoperative day 4

Hematocrit

Time frame: preoperative day 1

Hematocrit

Time frame: postoperative day 4

Platelet count

Time frame: preoperative day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.